• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.

作者信息

Ames M M, Powis G, Kovach J S, Eagan R T

出版信息

Cancer Res. 1979 Dec;39(12):5016-21.

PMID:115586
Abstract

The disposition and metabolism of pentamethylmelamine (PMM) and hexamethylmelamine (HMM) were studied in the rabbit, and the disposition of PMM was studied in humans. Parent compound and metabolites were identified by thin-layer chromatography, gas chromatography, and gas chromatography/mass spectrometry analyses. Plasma elimination in both species following i.v. administration of each drug was best described by a two-compartment open model. Both compounds were extensively demethylated with less than 1% of the total dose administered recovered in the urine over 24 hr. The areas under the plasma time-concentration curves of PMM and HMM following p.o. administration to rabbits were 5 and 25% of the areas following i.v. administration. Gastrointestinal absorption was rapid and efficient with 75 to 89% of drug equivalents recoverable in the urine after p.o. administration of [ring-14C]PMM or [ring-14C]HMM to rabbits. Reduced bioavailability of PMM and HMM p.o. appears to be a consequence of rapid metabolism presumably in the liver.

摘要

相似文献

1
Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
Cancer Res. 1979 Dec;39(12):5016-21.
2
Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism.由于肝脏和肠道同时进行代谢,六甲基三聚氰胺在大鼠体内的口服生物利用度较低。
Cancer Res. 1983 Jul;43(7):3160-4.
3
First-pass metabolism of pentamethylmelamine in the rat liver.五甲基三聚氰胺在大鼠肝脏中的首过代谢。
Cancer Res. 1985 Mar;45(3):983-6.
4
Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.六甲蜜胺和五甲蜜胺在小鼠体内的药代动力学
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):669-72.
5
Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.六甲蜜胺和五甲蜜胺在携带M5076/73A卵巢癌小鼠体内的组织分布
Cancer Treat Rep. 1982 Jan;66(1):127-33.
6
Pharmacokinetics of hexamethylmelamine in intralipid following hepatic regional administration in rabbits.六甲基三聚氰胺在兔肝脏区域给药后于脂肪乳剂中的药代动力学
Cancer Res. 1987 Oct 1;47(19):5070-3.
7
Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
Cancer Res. 1981 Apr;41(4):1402-6.
8
Absorption and metabolism of hexamethylmelamine and pentamethylmelamine in rat everted perfused gut segments: correlation with in-vivo data.六甲基三聚氰胺和五甲基三聚氰胺在大鼠外翻灌注肠段中的吸收与代谢:与体内数据的相关性
J Pharm Pharmacol. 1985 Sep;37(9):629-36. doi: 10.1111/j.2042-7158.1985.tb05099.x.
9
A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies.血浆中五甲基三聚氰胺的灵敏且特异的检测方法:在临床研究中的适用性。
Cancer Treat Rep. 1980 Jan;64(1):99-104.
10
Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Cancer Treat Rep. 1981 Sep-Oct;65(9-10):755-62.

引用本文的文献

1
Increased nephrotoxicity after combined administration of melamine and cyanuric Acid in rats.大鼠联合给予三聚氰胺和氰尿酸后肾毒性增加。
Lab Anim Res. 2011 Mar;27(1):25-8. doi: 10.5625/lar.2011.27.1.25. Epub 2011 Mar 26.
2
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.六甲蜜胺。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1995 Jun;49(6):932-53. doi: 10.2165/00003495-199549060-00007.
3
Hexamethylmelamine and hexamethylmelamine hydrochloride.
Pharm Weekbl Sci. 1982 Apr 23;4(2):25-31. doi: 10.1007/BF01963657.
4
The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.五甲基三聚氰胺在人、大鼠和小鼠体内的比较药代动力学。
Cancer Chemother Pharmacol. 1982;8(1):105-11. doi: 10.1007/BF00292880.
5
Dose-dependent pharmacokinetics of PMM in the rat.大鼠体内PMM的剂量依赖性药代动力学
Cancer Chemother Pharmacol. 1981;5(3):201-3. doi: 10.1007/BF00258481.
6
Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.五甲基三聚氰胺(PMM):I期临床及药代动力学研究。
Br J Cancer. 1983 Jan;47(1):27-33. doi: 10.1038/bjc.1983.3.
7
Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.肝脏激活系统对六甲蜜胺抗人肿瘤细胞系增殖活性的影响。
Cancer Chemother Pharmacol. 1985;15(1):49-53. doi: 10.1007/BF00257294.
8
N-methyl antitumour agents. A distinct class of anticancer drugs?N-甲基抗肿瘤药物。一类独特的抗癌药物?
Cancer Chemother Pharmacol. 1987;19(2):91-102. doi: 10.1007/BF00254559.
9
Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.六甲基三聚氰胺在肾细胞肿瘤小鼠体内的药代动力学与代谢
Cancer Chemother Pharmacol. 1988;22(4):282-8. doi: 10.1007/BF00254232.
10
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.N2,N4,N6-三羟甲基-N2,N4,N6-三甲基三聚氰胺(曲美莫)的临床前毒理学、药代动力学及制剂研究,曲美莫是一种水溶性细胞毒性均三嗪,无需代谢激活。
Cancer Chemother Pharmacol. 1986;17(3):251-8. doi: 10.1007/BF00256694.